Abstract:Since the discovery of rapamycin, considerable progress has been made in unraveling the details of the mammalian target of rapamycin (mTOR) signaling network, including the upstream mechanisms that modulate mTOR signaling functions, and the roles of mTOR in the regulation of mRNA translation and other cell growth-related responses. mTOR is found in two different complexes within the cell, mTORC1 and mTORC2, but only mTORC1 is sensitive to inhibition by rapamycin. mTORC1 is a master controller of protein synthesis, integrating signals from growth factors within the context of the energy and nutritional conditions of the cell. Activated mTORC1 regulates protein synthesis by directly phosphorylating 4E-binding protein 1 (4E-BP1) and p70S6K (S6K), translation initiation factors that are important to cap-dependent mRNA translation, which increases the level of many proteins that are needed for cell cycle progression, proliferation, angiogenesis, and survival pathways. In normal physiology, the roles of mTOR in both glucose and lipid catabolism underscore the importance of the mTOR pathway in the production of metabolic energy in quantities sufficient to fuel cell growth and mitotic cell division. Several oncogenes and tumor-suppressor genes that activate mTORC1, often through the phosphatidylinositol 3-kinase (PI3K)/AKT pathway, are frequently dysregulated in cancer. Novel analogs of rapamycin (temsirolimus, everolimus, and deforolimus), which have improved pharmaceutical properties, were designed for oncology indications. Clinical trials of these analogs have already validated the importance of mTOR inhibition as a novel treatment strategy for several malignancies. Inhibition of mTOR now represents an attractive anti-tumor target, either alone or in combination with strategies to target other pathways that may overcome resistance. The far-reaching downstream consequences of mTOR inhibition make defining the critical molecular effector mechanisms that mediate the anti-tumor response and associated biomarkers that predict responsiveness to mTOR inhibitors a challenge and priority for the field.

Mtor Signaling Pathway Regulates HIF-1α and VEGF

THE mTOR SIGNALING PATHWAY AND THE REGULATION OF CELL GROWTH

mTOR Signaling, Function, Novel Inhibitors, and Therapeutic Targets

Mtor Signaling Pathway and Apoptosis

Progress in mTOR study

Targeting Mtor for Cancer Therapy

Research Progress of Mtor Signaling Pathway and Non-Small Cell Lung Cancer

The mammalian target of rapamycin pathway and its role in molecular nutrition regulation.

Blocking Mammalian Target of Rapamycin (mTOR) Attenuates HIF-1α Pathways Engaged-Vascular Endothelial Growth Factor (VEGF) in Diabetic Retinopathy

The Mammalian Target of Rapamycin Pathway and Its Role in Molecular Nutrition Regulation

The progress of study on the biological function of mTOR pathway

STAT3/miR-130b-3p/MBNL1 feedback loop regulated by mTORC1 signaling promotes angiogenesis and tumor growth

Mtor Signaling Pathway and Cancer

Mtor Signaling in Cancer and Mtor Inhibitors in Solid Tumor Targeting Therapy

mTOR Signal Transduction Passageway and Myocardial Fibrosis

Mammalian target of rapamycin: discovery of rapamycin reveals a signaling pathway important for normal and cancer cell growth.

Post-translational Regulation of the Mtorc1 Pathway: A Switch That Regulates Metabolism-Related Gene Expression

Advance in the Mtor Signaling Pathway

Phosphoproteomic Analysis Implicates the Mtorc2-Foxo1 Axis in VEGF Signaling and Feedback Activation of Receptor Tyrosine Kinases.

Mammalian Target of Rapamycin as the Therapeutic Target of Vascular Proliferative Diseases: Past, Present, and Future

Mtor Signaling in Cardiometabolic Disease, Cancer, and Aging